LONGEVITY
Dr. Michael Zemel, CSO, NuSirt Biopharma commented:
“Therapies for extending health-span are on the near-term horizon and are well within reach provided there is a receptive regulatory environment to manage them. Longevity extension, on the other hand, may seem difficult to impossible, but in reality, this “impossibility” will just take a little longer in a supportive environment for clinical development.”
As the issue of aging population intensifies, sick care will become increasingly expensive and ineffective. The USA needs to rapidly deploy a government-led shift from treatment to prevention, and from prevention to precision health, using deep diagnostics and prognostics in combination with biomarkers of aging, metabesity, health and intervention-effectiveness, to delay the onset of disease with as minimal intervention as possible, as early as possible.
Breanna Deutsch, former Press Secretary and Communications Director for the U.S. Congress:
The drugs and treatments that have resulted from America’s commitment to medical science have benefited – and saved – countless lives. In order to continue leading the world in biomedical innovation, America’s policymakers and regulators must recognize the importance of longevity research and work to clear the federal roadblocks preventing this new era of medicine from reaching the hands of the public”
Tomoya Shintany, Laura Lema-Perez, and Hideva Shintany in: The Sugars with Potential to
Prolong Human Life (2021):
Geroprotector”, whose technical term Ilya Mechnikov first used in 1908 [79], means “protecting against aging”. The most important criterion of geroprotector is the ability to extend the lifespan of model organisms such as nematode fly and mice [80]. In 2001, Vladimir Anisimov suggested several types of geroprotectors using the most recognized theories of aging at that time as the typing criteria, which included antioxidants, neurotropic substances, hormones, antidiabetic drugs, immunomodulators, caloric restriction mimetics, and other substances and factors [81]. In the present, the various types would add longevity gene activators, includ- ing nicotinamide mononucleotide [82] and sirtuin activating compounds [83], as a new group to these conventional geroprotectors. Other new geroprotectors contain melatonin [84], and carnosine [85]. Among geroprotectors, the monosaccharides with the potential to prolong lifespan, mentioned in this chapter, is included in category of caloric restriction mimetics [49, 50]. This type of caloric restriction mimetics, whose action is considered glycolytic inhibition, mimics the anti- aging effects of long-term calorie restriction without requiring a change in eating
habits [68].
